Top level summary of results

Our Pymaceutical drug of interest (Capomulin) performance in reducing the volume of SCC tumors was compared against other drug regimens.

Ramicane performed best in reducing the mean Tumor Volume in mice (40.2) followed by our drug of interest (40.7). Hence our drug performed better than others apart from Ramicane.

Supported by the boxPlots, Capomulin and Ramicane had the lowest tumor volume compared to Infubinol and Ceftamin.

Similarly, based on the bar chart – Capomulin and Ramicane have the highest number of observed mice time points compared to the other drug regimens.

Specifically, the line chart illustrated the performance of our drug of interest based on time points (days). Capomulin treatment of mouse I509 decreased overall after 40 days.

However, more research is needed to determine why the an increase in Tumor volume at day 20.

These observations were not affected by gender as males (51.0%) and females (49.0%) had equal distribution during the sampling, hence eliminating any bias.

Finally, there was a positive strong correlation between the average tumor volume and mice weight for our drug of interest

In summary, our drug performed better than others and more research is needed to determine how weight could be correlating to tumor volume.